Current Trials Open to Enrollment

The USF Department of Psychiatry and Behavioral Neurosciences is currently enrolling patients in the following trials:

Adult Trials:

A 6-week trial of an investigational medication given IV as an add-on treatment for Major Depressive Disorder.   Individuals 18 to 65 years with Major Depression who are on an antidepressant and have experienced less than a 50% improvement in depressive symptoms may be eligible.  This program has two extension studies available. 

A 12-week study designed to determine the effectiveness of treatment with vortioxetine (Trintellix) on goal achievement after a change in antidepressant medication for the treatment of Major Depressive Disorder (MDD). Individuals 18-65 years with MDD who are changing from another antidepressant to vortioxetine per routine care may be eligible to enroll.

A study for Individuals 18 to 64 years with Treatment-resistant Depression investigating the effectiveness and safety of intranasal esketamine plus a newly initiated oral antidepressant compared with a newly initiated oral antidepressant (active comparator) plus intranasal placebo. The study will consist of 3 phases: Screening/Prospective Observational Phase (4-7 weeks), Double-blind Induction Phase (4-weeks), Follow-up Phase (24-weeks).  A long-term maintenance study is available. 

Please contact Colleen at 813-974-9104 ( or Yvonne at 813-974-2832 ( for more information. 

Children & Adolescent Trials:

A 10-week study of the drug levomilnacipran extended-release (ER) in adolescents, 12-17 years of age, with Major Depression.  

A 6-week study with an optional long-term study available, of an investigational medication (SPN-810) for the treatment of Impulsive Aggression in patients with Attention Deficit/Hyperactivity Disorder (ADHD) in conjunction with standard ADHD treatment.  Children 6-12 years old may be eligible.

Please contact Colleen at 813-974-9104 ( for more information.

Seniors (Age 65+) Trials:

A 24-month study for individuals 65-85 years of age who have been diagnosed with Mild Cognitive Impairment (MCI).  The study is investigating a medical food called ‘Vayacog’ compared to placebo to determine the effectiveness on cognition and memory. 

Please contact Kathy at 813-974-7006 ( for more information. 

Contact Information

For more information regarding current clinical trials, please call our Clinical Trial Information Line at (813) 974-1404, or contact the following:

Yvonne Bannon, RN, MSHS, CCRC
Phone: (813) 974-2832

Kathy Smith, RN
(813) 974-7006

Colleen Figueroa, BA
Phone: (813) 974-9104